Gsk (GSK) EBITDA (2009 - 2026)

Gsk (GSK) has 18 years of EBITDA data on file, last reported at $3.7 billion in Q3 2026.

• For the quarter ending Q3 2026, EBITDA changed N/A year-over-year to $3.7 billion; the trailing twelve-month figure through Sep 2026 stood at $13.1 billion (changed N/A YoY), and the FY2025 full-year result was $10.6 billion, up 105.27% from the prior year.
• EBITDA was $3.7 billion for Q3 2026 at Gsk, up from $645.3 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $5.6 billion in Q4 2025 to a low of $245.6 million in Q3 2024.
• A 5-year average of $2.8 billion and a median of $2.7 billion in 2025 frame the typical range for EBITDA.
• Across the five-year window, EBITDA tumbled 90.05% in 2024 and jumped 1324.82% in 2025, its largest moves.
• Gsk's EBITDA stood at $4.0 billion in 2022, then soared by 32.44% to $5.2 billion in 2023, then retreated by 23.21% to $4.0 billion in 2024, then jumped by 40.09% to $5.6 billion in 2025, then tumbled by 33.95% to $3.7 billion in 2026.
• Per Business Quant data, the three most recent EBITDA figures were $3.7 billion in Q3 2026, $645.3 million in Q2 2026, and $3.1 billion in Q1 2026.